about
Lipoatrophy in children with type 1 diabetes: an increasing incidence?"Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.Both the frequency of HbA1c testing and the frequency of self-monitoring of blood glucose predict metabolic control: A multicentre analysis of 15 199 adult type 1 diabetes patients from Germany and Austria.Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial.Pharmacological Properties of Faster-Acting Insulin Aspart.Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.Long-term Study of Tubeless Insulin Pump Therapy Compared to Multiple Daily Injections in Youth with Type 1 Diabetes: Data from the German/Austrian DPV-Registry.MD-Logic overnight type 1 diabetes control in home settings: A multicentre, multinational, single blind randomized trial.Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitusPharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes[The Way to Closed Loop - Dream and Reality]Adjusting insulin doses in patients with type 1 diabetes who use insulin pump and continuous glucose monitoring: Variations among countries and physiciansCombined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes CareOutcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm studyBeyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetesClinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case ReportsDREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabete
P50
Q36159081-E3D81854-D71C-4EE4-B027-B7D8460CC695Q37713057-D881F377-531F-4910-9EB8-20B9386114F9Q38381201-40737951-06EF-4B9B-9FC6-06C4621B16DBQ38763897-8EE82440-5DE5-4FF8-8F7D-81840F121BCEQ40423308-EB7C209A-F769-4440-85C0-A013D9B55F9DQ47288459-A6F19180-9146-4ACC-B5E0-27E29FC8B25AQ47937602-94F4BC4D-5950-4E5C-B56E-8729148674F2Q48267202-7B85DF0C-2CC4-4972-98AD-B85BA179EF9DQ49988118-023BDFDF-1BA7-47D0-84A7-37E3973FF98DQ51008011-B4AAABC2-7CE7-404F-B9AF-6917DF6F2FABQ54943513-B3DEF093-F4F1-40A4-8CA4-D50ABDC63673Q64767149-8331C1C0-525F-49E7-AD68-C342ADEA5223Q87109541-2103ACAF-75C4-4B7F-AE54-8CAE90D1D051Q88087718-5D0F0DA9-6A5B-42FE-9C62-E5A01F3C8DCAQ89048057-D4ECEFF3-9305-4900-B1D8-807A471A8880Q89148163-BFCA5558-DE21-45E5-A9C0-B80E3FC722DCQ90584245-803A2E45-F5E6-46AA-8604-1DED59087D58Q91970259-8EFDC110-890F-44CD-AB16-348D7C7BDDD3Q92674802-32F89606-E341-4CFD-A56E-80521597671CQ93384423-E648CCC0-4860-40B0-90AA-7026001311BD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Torben Biester
@ast
Torben Biester
@en
Torben Biester
@es
Torben Biester
@nl
type
label
Torben Biester
@ast
Torben Biester
@en
Torben Biester
@es
Torben Biester
@nl
prefLabel
Torben Biester
@ast
Torben Biester
@en
Torben Biester
@es
Torben Biester
@nl
P106
P214
96154440092835341198
P31
P496
0000-0001-8051-5562
P7859
viaf-96154440092835341198